----------------------------------------------------------
Chat real-time with other investors about this HSXI news release, by clicking this link: http://www.stockwire.com/HSXI
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=HSXI
HealthSonix, Inc. (PINKSHEETS: HSXI)
HealthSonix, Inc. closed at $0.24 Thursday, trading 181,750 shares.
Company News- September 26, 2007 HealthSonix and Abbott Laboratories Launch Innovative Combination Therapy Program for Patients With Advanced Rheumatoid Arthritis
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced Wednesday that the joint marketing program with Abbott Laboratories has commenced in
"The guidelines published by the
Abbott's biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in
"This new program represents a significant development in the fight against arthritis because the ACR guidelines stress that the combination of medications and non-pharmacological therapies is the optimal way to treat the patients," said Doederlein.
About HealthSonix, Inc. (PINKSHEETS: HSXI)
HealthSonix, Inc. (PINKSHEETS: HSXI) (
----------------------------------------------------------
Chat real-time with other investors about this HDVY news release, by clicking this link: http://www.stockwire.com/HDVY
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=HDVY
Health Discovery Corporation (OTCBB: HDVY)
Health Discovery Corporation closed at $0.105 Thursday, trading 318,295 shares.
Company News- September 28, 2007 Health Discovery Corporation Receives Notice of Allowance of
Health Discovery Corporation (HDC) (OTCBB: HDVY) announced earlier today that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for HDC's patent application covering a number of different feature selection techniques that can be used either in conjunction with or as an alternative to HDC's SVM patents using recursive feature elimination (RFE-SVM). These include minimizing the number of non-zero parameters of the system (or "zero-norm minimization"), evaluation of cost function to identify a subset of features compatible with constraints imposed by the learning set, unbalanced correlation score and transductive feature selection. It also describes a method that allows direct processing of multi-class problems instead of the more common practice of decomposing the problems into a multitude of two-class scenarios, thus providing for feature selection in the realm of multi-class and categorical regression problems. Examples are described for identifying the most relevant genes for classification of colon cancer and prostate cancer.
The named inventors include several of the world's leading authorities on SVMs and learning machines. Bernhard Schoelkopf, a member of HDC's Scientific Advisory Board, is a department director at the Max Planck Institute for Biological Cybernetics in
Once the USPTO issues this new patent, HDC will own and have exclusive rights to 29 U.S. and foreign SVM and FGM (fractal genomics modeling) patents for discovery of knowledge from large data sets, including methods and systems for pre-processing such data, analysis of data using multiple SVMs and for multiple data sets, computer-aided image analysis using SVMs, providing SVM analysis services over the Internet, and feature selection using SVMs. In addition, HDC's pending worldwide patent applications cover numerous improvements to and uses for SVMs including additional coverage of computer-aided image analysis (particularly for diagnosis using medical images), methods of feature selection for enhanced SVM efficiency, biomarkers for colon cancer, prostate cancer, BPH and renal cancer discovered with SVM methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.
"The pace of HDC's patent issuances and allowances in only the last six months has been quite remarkable for a firm of our size," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "For the past two years, our pioneering work in the SVM arena has been ripening into an extraordinary patent portfolio in the field of pattern recognition, and there's more to come. Only a few extremely large companies have received more SVM patents than HDC but, to the best of our knowledge, most or all of our SVM patent applications predate theirs. Interestingly though, we believe that HDC owns the world's only patents for the RFE-SVM which we feel is a revolutionary, and thus-far unique, development in pattern recognition methodologies. Our intellectual property estate continues to grow in value and I am confident we are on the threshold of monetizing these assets in a significant way." Savannah-based Health Discovery Corporation is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.
----------------------------------------------------------
Chat real-time with other investors about this ALRX news release, by clicking this link: http://www.stockwire.com/ALRX
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=ALRX
AlphaRx Inc. (OTC BB: ALRX)
AlphaRx Inc. closed at $0.08 Thursday, trading 200 shares.
Company News- September 28, 2007 AlphaRx Announces Debt Conversion
AlphaRx Inc. (OTCBB: ALRX), a specialty pharmaceutical company dedicated to developing the next generation of therapeutic products for inflammatory and infectious disease, announced earlier today the retirement of approximately $1.22 million of liabilities. Pursuant to a unanimous resolution of the Board of Directors, certain unsecured loans made to the Company by its directors, officers and third party investors, including earned and unpaid salaries and fees owed to employees and directors have been converted into shares of common stock of the Company. A total of 24,382,813 shares were issued for this conversion. The Company believes that the retirement of this debt is beneficial to it's financial condition and continued growth.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
----------------------------------------------------------
Chat real-time with other investors about this BLLB news release, by clicking this link: http://www.stockwire.com/BLLB
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=BLLB
Bell Buckle Holdings, Inc. (PINKSHEETS: BLLB)
Bell Buckle Holdings, Inc. closed at $0.135 Thursday, trading 2,010,997 shares.
Company News- September 28, 2007
Bell Buckle Holdings, Inc. (PINKSHEETS: BLLB) announced earlier today that on the heels of its exceptional distribution its third quarter sales will be its best sales quarter in its 10 year history. "Considering our recent news regarding Publix, Whole Foods, Kroger and several other nationally recognized chains distributing our products our third quarter mirrors the expanded distribution we have been so excited about announcing," stated company CEO, Brad Simmons. He continued, "With a 55% sales increase over this same time last year it confirms the public has accepted our extraordinary product line." As released recently Bell Buckle also announced that the launch of their Simplify brand Sugar-Free Pure Vanilla Extract has been more successful than anticipated. Simplify Pure Vanilla Extract is made using pure Madagascar Bourbon vanilla and is naturally sugar free, most vanilla extracts have corn syrups added. After a great deal of product testing and market research Bell Buckle Holdings, Inc. began offering Simplify Pure Vanilla Extract to the grocery market last month.
About Bell Buckle Holdings, Inc.
Bell Buckle Holdings Inc. was founded in 1995 as Bell Buckle Country Store, Inc., a family owned and operated business, dedicated to producing the finest all-natural gourmet food products on the market. This dedication to excellence has garnered recognition throughout the industry and many national awards for both taste and packaging. Through the years, the company has grown to include 5 brands, 239 products, sold in all 50 States and overseas through grocery stores, specialty gourmet & gift shops and big box retailers. Bell Buckle Country Store, Inc. products are sold under the brands: Captain Rodney's, Simplify, Bell Buckle Country Store, Rose & Ivy and Bainbridge Festive Foods.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
